[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unstable-angina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unstable-angina":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,83,108,132,156,180,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629214","prospective-lifespan-cohort-of-myocardial-infarction-100629214",false,"NCT07471763","Prospective Lifespan Cohort of Myocardial Infarction","A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System","Inclusion Criteria:\n\nAge 18 to 74 years\n\nDiagnosed with stable angina, unstable angina, or acute myocardial infarction\n\nFor acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized\n\nDiagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction\n\nWilling to participate and able to provide written informed consent\n\nAble to complete baseline assessment, biospecimen collection, and long-term follow-up\n\nExclusion Criteria:\n\nEnd-stage malignant tumor with expected survival of less than 1 year\n\nSevere hepatic or renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or Child-Pugh class C)\n\nActive autoimmune disease or long-term use of immunosuppressive agents\n\nPregnant or breastfeeding women\n\nInability to provide informed consent or severe cognitive impairment\n\nPrevious participation in another clinical study that may conflict with this project\n\nAny other condition considered by the investigators to make participation inappropriate","ALL","18 Years","74 Years",{"count":20,"type":21},6000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.\n\nThe study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.\n\nThe primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.",[25,26,27],"Acute Myocardial Infarction (AMI)","Stable Angina","Unstable Angina",[29,30,31,32,33,34,35],"prospective cohort","multi-omics","artificial intelligence","risk prediction","precision medicine","acute myocardial infarction","lifespan cohort","NOT_YET_RECRUITING","2026-03-22",{"date":39,"type":40},"2026-03-25","ACTUAL",{"date":42,"type":21},"2026-04-10",{"date":44,"type":21},"2031-04-10",{"name":46,"class":47},"Fujian Provincial Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100621308","advanced-nanotherapies-dual-api-dcb-to-treat-de-novo-and-isr-lesions-in-patients-with-symptomatic-coronary-artery-disease-100621308","NCT07368933","Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease","ADVANCEd NanoTherapies SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter to Treat Coronary In-stent Restenosis (ISR) and de Novo Lesions","ADVANCE-DUO","Inclusion Criteria:\n\n1. ≥18 years or minimum legal age as required by local regulations.\n2. Documented stable or unstable angina, positive functional test, or non -ST elevation myocardial infarction which, in the judgment of the operator, is attributable to disease in coronary vessel or in-stent restenosis, and the patient is deemed an appropriate candidate for PCI in accordance with the applicable guidelines on percutaneous coronary intervention.\n\n   Note: participants with NSTEMI must have enzymes that are trending down or are within normal limits prior to enrollment.\n3. Life expectancy \\>1 year in the Investigator's opinion.\n4. Participant is willing and able to cooperate with study procedures and follow-up evaluations.\n5. Treatment of only one target lesion required\n\n   1. Tandem lesions treated by a single DCB will be considered one target lesion.\n   2. Up to one de novo lesion in a separate vessel may be treated per standard of care at the procedure. Non-target lesions must be successfully treated under the same criteria of the target lesion, before treating the target lesion.\n6. Target lesion must be ≤36 mm in length.\n7. Target lesion must have a stenosis ≥ 50% and \\\u003C 100%.\n8. Target lesion must have a visually estimated reference vessel diameter of:\n\n   1. ISR lesions: 2.0 to 4.0 mm in diameter (inclusive)\n   2. de novo lesions: 2.0 to \\\u003C3.0 mm in diameter\n9. ISR lesions only: target lesion must be within a previous BMS or DES that does not extend \\>5.0 mm beyond the proximal or distal edge.\n\nExclusion Criteria:\n\n1. Participant is pregnant, or breastfeeding. Note: Participant of childbearing potential must have a negative pregnancy test within 7 days before procedure.\n2. Known hypersensitivity or contraindication to antiplatelet medications (e.g., aspirin; heparin; prasugrel); or a sensitivity to contrast media which cannot be adequately pre-medicated.\n3. History of an allergic reaction or significant sensitivity to paclitaxel, sirolimus, or any other analogue or derivative.\n4. Platelet count \\\u003C 100,000 cells\u002Fmm³ (i.e., 100 x 109 \u002FL) or \\> 700,000 cells\u002Fmm³ (i.e., 700 x 10 9 \u002FL), or a white blood cell (WBC) count \\\u003C 3,000 cells\u002Fmm³ within 7 days prior to procedure.\n5. Renal insufficiency (Serum creatinine level \\> 2.5 mg\u002Fdl (i.e., 221 μmol\u002FL) within 7 days prior to procedure) or failure (dialysis dependent).\n6. Evidence of an acute MI within 72 hours of the procedure Note: participants with NSTEMI are allowed, provided enzymes are trending down or are within normal limits prior to enrollment.\n7. Previous PCI of the target vessel within 6 months prior to procedure.\n8. History of a stroke or transient ischemic attack (TIA) within the prior 3 months to procedure (any prior stroke or TIA, if prasugrel is used).\n9. Planned PCI of any vessel within 30 days post-procedure and\u002For planned PCI of the target vessel within 12 months post-procedure.\n10. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months to procedure.\n11. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.\n12. Documented left ventricular ejection fraction (LVEF) \\\u003C30% at the most recent evaluation, within the prior 3 months to procedure.\n13. Planned surgery that would cause interruption in recommended DAPT duration per current guidelines.\n14. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS, or other coronary artery imaging procedures.\n15. The following criteria related to previous treatments applies based on the type of lesion treated. The participant is excluded in the following circumstances:\n\n    1. ISR lesions: If single-layer ISR, any previous treatment of the target vessel for restenosis. If double- layer ISR, any treatment of the double-layer ISR.\n    2. de novo lesions: any previous treatment of the target lesion.\n16. Planned PCI of three vessel disease during procedure.\n17. Planned treatment of more than one target vessel. Tandem lesions that can be treated by a single DCB are permissible.\n18. Target lesion requires treatment with atherectomy, laser, or thrombectomy procedure.\n19. Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate.\n20. Target vessel has evidence of thrombus.\n21. Target vessel is excessively tortuous, defined as more than one bend \\>90° to reach target lesion.\n22. Target lesion has any of following characteristics:\n\n    1. Lesion location is unprotected in left main coronary artery, internal mammary artery, aorto-ostial, bypass grafts, ostial lesions or within 5 mm of the origin of the left anterior descending or left circumflex.\n    2. Involves a side branch \\>2.0 mm in diameter.\n    3. Is severely calcified.\n23. The following criteria based on number and type of lesions:\n\n    1. ISR and de novo lesions: target lesion is in the same vessel with a de novo lesion requiring treatment.\n    2. ISR lesions: planned treatment of a ≥3 layer ISR lesion.",{"count":58,"type":21},30,"INTERVENTIONAL",[61],"NA","The study objectives are:\n\n1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease.\n2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \\\u003C3.00 mm in diameter in patients with symptomatic coronary artery disease.",[64,65,27,66],"Angina (Stable)","CAD - Coronary Artery Disease","NSTEMI - Non-ST Segment Elevation MI",[68,69,70],"DCB","Drug Coated Balloon","Coronary Artery Disease","RECRUITING","2026-01-23",{"date":74,"type":40},"2026-01-27",{"date":76,"type":40},"2025-12-15",{"date":78,"type":21},"2029-01",{"name":80,"class":81},"Advanced NanoTherapies","INDUSTRY",3,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":59,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100566603","leaders-free-iv-rct-biofreedom-ultra-vs-biofreedom-in-hbr-patients-100566603","NCT06657326","LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients","Evaluation of the Efficacy (QCA) and Safety of the BioFreedom™ Ultra Drug Coated Stent in Patients With High Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","Inclusion Criteria:\n\n1. Patients at high bleeding risk (HBR) with an indication for PCI who can tolerate at least one month of DAPT. This includes patients with stable angina, silent ischemia, acute coronary syndromes (ACS) (STEMI and NSTEMI), de novo lesions in native arteries with diameter stenosis \\>70% by visual estimation and evidence of ischemia in the territory of the target vessel(s).\n2. Patients meet ARC-HBR definition i.e at least 1 major or 2 minor criteria.\n\nExclusion Criteria:\n\n1. Pregnant and breastfeeding women\n2. Age \\\u003C18 years old\n3. Patients lacking capacity (i.e. patients suffering from dementia and others) to provide informed consent\n4. Patients expected not to comply with 1 month DAPT\n5. Active bleeding at the time of inclusion\n6. Procedure requires the use of non-study stents, or alternative therapeutic options not followed by stent implantation (angioplasty only, atherectomy only)\n7. Number of target lesions \\>2\n8. Patient requires a stent of diameter \\\u003C2.25mm\n9. Patient requires a stent of diameter \\>4.0mm\n10. Isolated ostial lesions within 3 mm of the origin of LAD or LCx (left main lesions involving the ostia of the LAD and\u002For LCx are eligible)\n11. Patient has known left ventricular ejection fraction (LVEF) \\\u003C30% (LVEF may be obtained at the time of the index procedure if the value is unknown and the investigator believes it is necessary)\n12. Patient with chronic total occlusion(s) as target lesion(s)\n13. Severe calcification that might prevent sufficient expansion of the DES, unless pre-treated with a plaque modification device such as cutting balloon, scoring balloon or intravascular lithotripsy.\n\n    Note: Use of rotational or orbital atherectomy is also permitted.\n14. Cardiogenic shock\n15. Compliance with long-term single anti-platelet therapy unlikely\n16. Known hypersensitivity or contraindication to aspirin, clopidogrel (or to any other P2Y12 inhibitor if applicable), cobalt chromium, stainless steel, zinc, Biolimus A9™ or a sensitivity to contrast media, which cannot be adequately pre-medicated\n17. Any PCI during the previous 12 months\n18. Participation in another clinical study (12 months after index procedure)\n19. Patients with a life expectancy of \\\u003C12 months",{"count":91,"type":21},444,[61],"This study aims to demonstrate that the BioFreedom™ Ultra Drug Coated Stent (DCS) is non-inferior to the BioFreedom™ DCS, with respect to in-stent late lumen loss, and that it has safety characteristics similar to the BioFreedom™ DCS.",[70,95,27,96,97],"Chronic Stable Angina","Silent Ischemia","Acute Coronary Syndrome","2025-06-03",{"date":100,"type":40},"2025-06-05",{"date":102,"type":40},"2024-12-18",{"date":104,"type":21},"2030-12",{"name":106,"class":81},"Biosensors Europe SA",6,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":22,"phases":4,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100549597","japanese-coronary-intervention-using-drug-eluting-and-perfusion-therapy-for-left-main-disease-jdepth-lm-registry-100549597","NCT06436092","Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patient with stable coronary artery disease, non-ST-elevation myocardial infarction, or unstable angina\n3. Left main disease confirmed by coronary angiography or coronary CT angiography\n4. Clinical and anatomical eligibility for PCI as agreed by the local Heart Team\n5. Patient with consent prior to undergoing PCI\n6. Left main Medina classification (1,1,1), (1,0,1), (0,1,1), (0,0,1) confirmed by coronary angiography\n7. De novo target lesion in LMT-LAD amenable for crossover stenting with provisional side-branch approach as determined by PCI operator\n8. De novo ostial LCx lesions\n9. Lesion indicated in No. 8 with a length of less than 10 mm or a stenosis of less than 70% confirmed by coronary angiography\n\nExclusion Criteria:\n\n1. Inability to provide written informed consent\n2. Patient with a history of ST-elevation myocardial infarction within the previous 1 week\n3. Patient in a state of cardiogenic shock\n4. Patient with a history of coronary artery bypass grafting\n5. Patient with malignant tumors or other conditions with a life expectancy of less than one year\n6. Patient considered suitable for stent placement in the ostial LCx from a medical perspective\n7. Patient considered unsuitable for anti-thrombotic therapy after PCI\n8. Other patient whom the investigator deems unsuitable for the safe conduct of LM-PCI, including W-KBT",{"count":115,"type":21},280,"12 Months","JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI) using Perfusion balloon (PB) and Drug coated balloon (DCB) in patients with left main coronary artery disease (LMD) with left circumflex artery (LCx) ostium stenosis.",[26,119,27],"Non-ST-elevation Acute Coronary Syndrome",[121],"Ischemic heart disease","2025-03-11",{"date":124,"type":40},"2025-03-13",{"date":126,"type":40},"2024-05-27",{"date":128,"type":21},"2029-12-31",{"name":130,"class":81},"TCROSS Co., Ltd.",32,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":59,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":48},"100532683","treatment-of-acute-coronary-syndromes-with-low-dose-colchicine-100532683","NCT06215989","Treatment of ACuTe Coronary Syndromes With Low-dose colchICine","Treatment of ACuTe Coronary Syndromes With Low-dose colchICine (TACTIC): a Randomised, Double-blinded, Placebo-controlled, Multicentric Trial","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Definite diagnosis of ACS;\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Type 2 myocardial infarction (Patients with symptoms or signs of myocardial ischemia and evidence of increased oxygen demand or decreased supply \\[for example, tachyarrhythmia, hypotension, or anaemia\\] secondary to an alternative pathology and myocardial necrosis are defined as suffering type 2 myocardial infarction. The classification of type 2 myocardial infarction also includes patients with coronary vasospasm, embolism or spontaneous dissection without evidence of atherothrombosis related to coronary artery disease);\n* Valvular heart disease that is considered likely to require surgical intervention;\n* History of non-skin cancer in the past 3 years;\n* Inflammatory bowel disease or chronic diarrhea;\n* History of gastric ulcer or previous gastric bleeding;\n* Neuromuscular diseases or non-transient (At least 2 laboratory tests) creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n* Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities(Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n* Estimated glomerular filtration rate (eGFR)\\\u003C30mL\u002Fmin\u002F1.73m2 (based on CKD-EPI formula);\n* Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders(INR\\>1.5)(except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n* Decline in cognitive function due to inability to perform basic activities of daily living independently;\n* Drug or alcohol abuse;\n* Other immunosuppressive therapies already in existence or planned;\n* Other causes require long-term colchicine treatment;\n* History of clear or suspected colchicine allergy;\n* Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.",{"count":140,"type":21},6574,[61],"This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[97,27,144,145,146],"ST Elevation Myocardial Infarction","Non ST Segment Elevation Myocardial Infarction","Colchicine","2024-10-27",{"date":149,"type":40},"2024-10-30",{"date":151,"type":40},"2024-09-02",{"date":153,"type":21},"2028-06",{"name":155,"class":47},"Beijing Anzhen Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100554137","european-survey-of-cardiovascular-disease-prevention-diabetes-and-chronic-kidney-disease-euroaspire-vi-100554137","NCT06495177","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)","European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease","EUROASPIRE VI","Inclusion Criteria:\n\n* Patients having signed an informed Consent\n* Patients aged from 18 years old at the time of identification\n* At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview\n* Patients meeting the recruiting diagnostic or treatment criteria:\n* Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI)\n* High cardiovascular disease (CVD) risk patients: patients free of CVD, who have been prescribed one or more of the following treatments: blood pressure and\u002For lipid-lowering and\u002For glucose lowering (diet and\u002For hypoglycaemic agents and\u002For insulin)\n\nExclusion Criteria:\n\n* Patients living outside defined geographical areas\n* Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI",{"count":165,"type":21},8000,"The goal of this observational study is to provide a unique European picture of preventive action by cardiologists, other specialists and primary care physicians looking after patients with coronary heart disease (CHD), individuals at high cardiovascular disease risk and all those with hypertension, dyslipidaemia (including familial hypercholesterolaemia), diabetes and dysglycaemia and chronic kidney disease (CKD) and determine whether the European guidelines on cardiovascular disease prevention, hypertension, lipids, diabetes and chronic kidney disease are being followed.",[168,97,27,144,169],"Coronary Disease","Non-ST Elevation Myocardial Infarction","2024-07-02",{"date":172,"type":40},"2024-07-10",{"date":174,"type":40},"2024-06-07",{"date":176,"type":21},"2029-12",{"name":178,"class":179},"European Society of Cardiology","NETWORK",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":48},"100494543","a-cohort-of-patients-undergoing-percutaneous-coronary-intervention-100494543","NCT05719545","A Cohort of Patients Undergoing Percutaneous Coronary Intervention","A Longitudinal Cohort of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention","APCIcohort","Inclusion Criteria:\n\n* Diagnosed as acute coronary syndrome and needed to undergo percutaneous coronary intervention.\n* \\>18 years old.\n\nExclusion Criteria:\n\n* With malignant tumors, acute infectious diseases and advanced liver diseases.\n* Won't sign an inform consent.","85 Years",{"count":190,"type":21},10000,"To investigate the risk factors involved in the occurrence and prognosis of the patients with acute coronary syndrome, patients undergoing percutaneous coronary intervention will be recruited and followed up for at least 2 years.",[97,193,194,27],"Percutaneous Coronary Intervention","Myocardial Infarction","2023-01-31",{"date":197,"type":40},"2023-02-09",{"date":199,"type":40},"2021-12-01",{"date":201,"type":21},"2026-12-30",{"name":203,"class":47},"Su Guohai",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":211,"targetDuration":4,"studyType":59,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":48},"100456965","prospective-evaluation-of-complete-revascularization-in-patients-with-multivessel-disease-excluding-chronic-total-occlusions-100456965","NCT05230446","PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions","PRESENT","Inclusion Criteria:\n\n1. Age ≥ 18 years, ≤85 years\n2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki\n3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.\n4. The patient is willing and able to cooperate with study procedures and required follow up visits\n5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\> 85 years.\n2. Single coronary vessel disease.\n3. No left anterior descending lesion.\n4. Patients in cardiogenic shock.\n5. Patients with STEMI.\n6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.\n7. Left main coronary artery disease\n8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.\n9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.\n10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement\n11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.\n12. Previous coronary artery bypass grafting (CABG).\n13. Patient requiring additional cardiac surgery within 6 months.\n14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.",{"count":212,"type":21},609,[61],"This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).",[216,169,27,26,70,193,217],"Multi Vessel Coronary Artery Disease","Optical Coherence Tomography","2022-01-25",{"date":220,"type":40},"2022-02-09",{"date":222,"type":40},"2021-11-18",{"date":224,"type":21},"2027-11-18",{"name":226,"class":47},"Erasmus Medical Center"]